MRI影像组学预测胶质瘤1p/19q共缺失状态:诊断准确性的系统评价与Meta分析
该系统评价与Meta分析评估MRI影像组学模型预测胶质瘤1p/19q共缺失状态的效能,检索4个数据库,28项研究纳入系统评价,其中10项进入Meta分析。合并敏感度0.82(95%CI 0.67-0.91)、特异度0.80(95%CI 0.70-0.88)、AUC 0.87(95%CI 0.84-0.90),提示模型具有良好的无创预测性能。
要点
- MRI影像组学模型预测胶质瘤1p/19q共缺失的合并AUC为0.87(95%CI 0.84-0.90)。
- 合并敏感度0.82(95%CI 0.67-0.91),特异度0.80(95%CI 0.70-0.88)。
- 亚组分析显示基于国家和分割方法的差异有统计学意义。
核心结论
- MRI影像组学模型对胶质瘤1p/19q共缺失状态表现出良好的预测性能,提示其作为无创工具用于胶质瘤特征描述和辅助治疗决策的潜力。
研究设计与样本
- 系统评价与诊断准确性Meta分析,检索PubMed、Web of Science、EMBASE和Scopus共4个数据库,28项研究纳入系统评价,其中10项纳入Meta分析;采用Methodological Radiomics Score评价研究质量,以I²统计量评估异质性,Deek's漏斗图评估发表偏倚。
诊断标准与关键数值
- Meta分析(10项研究)合并敏感度0.82(95%CI 0.67-0.91),特异度0.80(95%CI 0.70-0.88)。
- 合并阳性诊断似然比4.14(95%CI 2.62-6.52),阴性诊断似然比0.23(95%CI 0.12-0.43)。
- 合并诊断比值比18.37(95%CI 7.36-45.85),AUC 0.87(95%CI 0.84-0.90)。
局限性
- Meta分析受限于具有外部验证队列的研究数量较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: The 1p/19q codeletion is a key genetic marker in gliomas and plays a crucial role in prognosis and treatment decisions. Traditional methods for detecting this genetic alteration rely on invasive tissue biopsies.
PURPOSE: This systematic review and meta-analysis aimed to evaluate the performance of MRI-derived radiomics-based models to predict glioma 1p/19q codeletion status.
DATA SOURCES: A literature search was conducted in 4 databases: PubMed, Web of Science, EMBASE, and Scopus.
STUDY SELECTION: We selected the studies that assessed the performance of radiomics-based models in determining 1p/19q codeletion status.
DATA ANALYSIS: The Methodological Radiomics Score was used to evaluate study quality. Pooled diagnostic estimates were calculated, and heterogeneity was assessed by using the I 2 statistic. Subgroup and sensitivity analyses were performed to investigate potential sources of heterogeneity. Deek's funnel plot was used to assess publication bias.
DATA SYNTHESIS: Twenty-eight studies met the inclusion criteria for the systematic review. A meta-analysis of 10 studies yielded a pooled sensitivity of 0.82 (95% CI, 0.67-0.91), specificity of 0.80 (95% CI, 0.70-0.88), positive diagnostic likelihood (DLR) of 4.14 (95% CI, 2.62-6.52), negative DLR of 0.23 (95% CI, 0.12-0.43), diagnostic odds ratio of 18.37 (95% CI, 7.36-45.85), and area under the curve of 0.87 (95% CI, 0.84-0.90). Subgroup analysis revealed significant differences based on the country and segmentation method.
LIMITATIONS: Our meta-analysis is limited by small number of studies with external validation cohorts.
CONCLUSIONS: MRI-derived radiomics-based models demonstrated good predictive performance for glioma 1p/19q codeletion status, highlighting their potential as a noninvasive tool for glioma characterization and for aiding in treatment decision-making.
引用
- Ahmadzadeh AM, Lomer NB, Ashoobi MA, et al. Predicting 1p/19q Codeletion Status in Glioma Using MRI-Derived Radiomics: A Systematic Review and Meta-Analysis of Diagnostic Accuracy. AJNR Am J Neuroradiol. 2025. PMID: 40194850. doi:10.3174/ajnr.A8771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。